Showing results (61-70 of 74) with videos related to
Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2013
BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damageVictoria J Mar, Stephen Q Wong, Jason Li, et al.Drug Design, Development and Therapy|April 8, 2020
A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in AustraliaJason D Lickliter, Hui K Gan, Mark Voskoboynik, et al.Cancer Immunology Research|September 17, 2020
Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of MelanomaPouya Faridi, Katherine Woods, Simone Ostrouska, et al.Cell Death & Disease|April 26, 2019
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survivalErinna F Lee, Tiffany J Harris, Sharon Tran, et al.Cell Reports|February 24, 2024
PRMT1 acts as a suppressor of MHC-I and anti-tumor immunityTirta M Djajawi, Lizzy Pijpers, Akash Srivaths, et al.Nature Immunology|July 16, 2024
Vγ9Vδ2 T cells recognize butyrophilin 2A1 and 3A1 heteromersThomas S Fulford, Caroline Soliman, Rebecca G Castle, et al.Science Immunology|October 6, 2023
TCF-1 limits intraepithelial lymphocyte antitumor immunity in colorectal carcinomaMarina H Yakou, Sonia Ghilas, Kelly Tran, et al.Nature|August 17, 2017
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunityMarian L Burr, Christina E Sparbier, Yih-Chih Chan, et al.Science (New York, N.Y.)|January 11, 2020
Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cellsMarc Rigau, Simone Ostrouska, Thomas S Fulford, et al.Cell Reports|December 20, 2025
A TAK1 cytokine toxicity checkpoint controls anti-cancer immunityTirta M Djajawi, Anne Huber, Sarahi Mendoza Rivera, et al.Pageof 8